Ascend, 3M team for cancer vaccine research
Ascend has arranged to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 by chemically conjugating it with Ascend’s ASN platform.
ASN is an antigen-presenting, cell-targeting and delivery technology that allows vaccine antigens and immune modulators to be selectively targeted to specialised antigen presenting cells.
Under the agreement, 3M will provide GLP and GMP material for preclinical and clinical studies into the potency of 3M-051 conjugated with Ascend’s ASN platform. The preclinical immunogenicity trials will last up to 12 months.
Ascend CEO Dr Clement Leong said the company is embarking on the evaluation based on research suggesting its ASN platform can allow the generation of a strong cytotoxic CD8+ T cell response to a vaccine antigen in addition to a strong antibody response.
“Our research has demonstrated encouraging clinical and immunological responses and we believe the chemical conjugation of a potent TLR agonist could confer further improvements to the previously observed clinical responses,” he said.
Ascend is preparing to enter clinical trials for two cancer vaccine candidates, with an initial focus on breast cancer and basal cell carcinoma respectively.
The removal of male hormones in sheep delays ageing of DNA, and also drives feminine...
New research led by Finland's University of Oulu refutes the belief that high haemoglobin...
All individuals aged 18 years and above in Greater Sydney should strongly consider getting...